We therefore designed a first-in-man study of the feasibility and safety of IVT ERT in human CLN2 patients to test the hypothesis that IVT ERT could slow down the progression of retinal dystrophy in CLN2 patients also receiving ICV ERT. The gene discussed is TPP1; the disease is inherited retinal dystrophy.